Lupin gets FDA approval for generic drug to treat postmenopausal osteoporosis
Advertisement
New Delhi: Drug major Lupin has received US health regulator's approval to market Fyavolv tablets, used to treat postmenopausal osteoporosis, in the American market.
The company has received received the final approval from the United States Food and Drug Administration (FDA) to market Fyavolv tablets, Lupin on Monday said in a statement.
"Lupin's US subsidiary, Lupin Pharmaceuticals Inc shall commence promoting the product in the US shortly," it added.
The company's product is the generic equivalent of Warner Chilcott's Femhrt tablets, which are indicated for the treatment of moderate to severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis.
According to IMS MAT September data, Femhrt had US sales of $39.9 million.
The Mumbai-based firm has launched eight products in the US this fiscal and received approvals for 19 from the FDA.
The company's cumulative abbreviated new drug application (ANDA) filings with the USFDA stood at over 220 with the company having received 131 approvals to date.
The company has received received the final approval from the United States Food and Drug Administration (FDA) to market Fyavolv tablets, Lupin on Monday said in a statement.
"Lupin's US subsidiary, Lupin Pharmaceuticals Inc shall commence promoting the product in the US shortly," it added.
The company's product is the generic equivalent of Warner Chilcott's Femhrt tablets, which are indicated for the treatment of moderate to severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis.
According to IMS MAT September data, Femhrt had US sales of $39.9 million.
The Mumbai-based firm has launched eight products in the US this fiscal and received approvals for 19 from the FDA.
The company's cumulative abbreviated new drug application (ANDA) filings with the USFDA stood at over 220 with the company having received 131 approvals to date.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.